Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Merck & Co. (MRK) stock surged 12.6% to a record $152.20 on August 19 following a landmark melanoma trial confirming the efficacy of its personalized mRNA cancer therapy, intismeran, in combination with Keytruda. The Phase 3 INTerpath-001 study involving 1,137 patients demonstrated statistically and clinically significant enhancements in recurrence-free survival and distant-metastasis-free survival compared to Keytruda alone.

Keytruda sales generated $31.68 billion for Merck in 2025, representing nearly half of the company's total sales. The success of intismeran could potentially prolong the relevance of Keytruda beyond the expiration of its patent in December 2028, as biosimilars have already entered some smaller international markets. Merck's investment in intismeran extends Keytruda's growth runway, yet the economics of personalized therapy and shared profits with Moderna limit immediate financial impact.

While the melanoma win bolsters Merck's oncology outlook, investors should recognize that the 12.6% rally also accounts for speculative possibilities. The data highlights the potential of intismeran to create a portfolio of Keytruda combinations across various cancer types, reinforcing the argument that Keytruda can maintain commercial relevance post-patent cliff.

However, the development challenges and higher costs of personalized therapy could hinder immediate financial gains.